TLDR
- NextCure (NXTC) stock surged over 300% Tuesday after announcing an all-stock merger with private biotech Avere Therapeutics
- The deal includes a concurrent $320 million private placement led by Fairmount and Hansoh Pharmaceutical
- The combined company will trade on Nasdaq under the ticker AVRX, expected to close in the second half of 2026
- NextCure stockholders will own approximately 1.21% of the combined company
- The merger centers on AVR-001, an oral once-weekly IL-23 receptor blocker targeting psoriasis and ulcerative colitis
NextCure (NXTC) stock exploded over 300% on Tuesday after the clinical-stage biotech announced a merger with privately-held Avere Therapeutics in a deal backed by $320 million in fresh financing.
Despite the massive single-day move, the stock remains down roughly 84% year-to-date, with a market cap of just $7.87 million heading into the announcement.
The all-stock transaction will see the combined company operate under the Avere Therapeutics name and trade on Nasdaq under the ticker symbol AVRX. The deal is expected to close in the second half of 2026.
The $320 million private placement includes $251 million in convertible notes that will convert to common stock at closing. Fairmount and Hansoh Pharmaceutical led the round, with participation from Venrock Healthcare Capital Partners, General Atlantic, Janus Henderson Investors, and Wellington Management.
The merger is built around Avere’s lead asset, AVR-001 — a once-weekly oral IL-23 receptor antagonist being developed for inflammatory conditions including psoriasis and ulcerative colitis.
Avere recently licensed AVR-001 from Hansoh, covering rights outside Greater China. Hansoh received $120 million upfront and is eligible for up to $2.18 billion in development and sales milestone payments, plus royalties.
The new financing is designed to fund a Phase 2b psoriasis trial, the start of a Phase 3 psoriasis study, and a Phase 2b ulcerative colitis study. A US IND for AVR-001 is already open, with Phase 2b initiation expected in early 2027 and a readout expected in the first half of 2028.
Who’s Running the Show
Avere CEO Dr. Andrew Cheng will lead the combined company as CEO, President, and Chairman. Kitty Yale steps in as Chief Development Officer, William White as CFO, and Brett Pletcher as General Counsel.
NextCure’s current CEO Michael Richman called the deal “a compelling opportunity” for stockholders to participate in AVR-001’s development.
What NextCure Holders Get
NextCure stockholders will hold approximately 1.21% of the combined entity — reflecting the company’s current size relative to Avere.
They will also receive contingent value rights entitling them to 90% of net proceeds from any future monetization of NextCure’s existing pipeline assets for two years after closing.
Trading volume on Tuesday topped 44 million shares. That compares to a three-month average daily volume of around 37,000 shares.
Wall Street’s consensus on NXTC is a Moderate Buy, based on two Buy ratings in the past three months, with an average price target of $20 per share.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
